Corporate Governance and Bioethics of Biomedical Capital Formation in Latin America

Abstract

The formation of biomedical capital in Latin America has become central to contemporary health innovation, investment strategies and the regional consolidation of corporate governance structures that regulate clinical data, biobanking, pharmaceutical development and the circulation of knowledge derived from human biological materials. In this context, bioethics functions not only as a normative safeguard but also as a framework through which legitimacy, transparency and distributive justice can be evaluated in relation to public and private biomedical ventures. This study analyzes how corporate governance mechanisms intersect with bioethical principles in shaping biomedical capital formation across Mexico, Colombia, Chile and Argentina. A mixed-methods design was implemented, combining documentary analysis of regulatory frameworks, statistical data on R&D investment and qualitative interviews with 36 key informants, including researchers, policymakers and private-sector actors. Results reveal persistent asymmetries in regulatory enforcement, weak alignment between governance standards and bioethical safeguards, and emerging conflicts involving data ownership, consent models, and commercial uses of genomic information. Quantitative findings from three comparative tables show increasing private-sector dominance in biomedical patenting, limited public oversight and significant gaps in ethical review capacity. Interview excerpts complement these results by illustrating tensions between innovation incentives and respect for autonomy, community benefit and equity. The discussion interprets these findings in the context of global health capital markets and Latin America’s structural vulnerabilities. The study concludes by proposing a regional governance-bioethics integration model emphasizing transparency, cross-border regulatory harmonization and participatory mechanisms for biomedical decision-making